Consolidated revenues to grow 20% next year: Dishman Pharma

5265 Investors following Dishman Pharma. Share this News with them.

0

Like this story, share it with millions of investors on M3

Consolidated revenues to grow 20% next year: Dishman Pharma

In an interview with CNBC-TV18, VVS Murthy, Chief Financial Officer, Dishman Pharma, spoke about the latest happenings in his company and sector.

Post your opinion here

 

0

Tweet

Share on Tumblr

Excerpts from Midcap Radar on CNBC-TV18 Watch the full show » RELATED NEWS Dishman Pharma plant receives US FDA approval ALSO READ See latest News about Dishman Pharma See previous management interviews See what other Experts & Brokerages are saying about Dishman Pharma Dishman Pharma BSE | NSE 30/05/12 Are Mutual Funds betting on Dishman Pharma?

In an interview with CNBC-TV18, VVS Murthy, Chief Financial Officer, Dishman Pharma , spoke about the latest happenings in his company and sector.

Here is a verbatim transcript of the exclusive interview with VVS Murthy on CNBC-TV18. Also watch the accompanying video.

Q: You didn't have a very good Q3 because of Carbogen Amcis, but your CRAMS (Contract Research and Manufacturing Services) business was good. Outline for us how FY11 will pan out since a lot of your capex plans kick in at that time?

A: On overall consolidated basis, we are expecting about 20% growth in consolidated revenues next year, largely driven by manufacturing contracts. But contract research would be a little dull for maybe another two-three quarters.

Q: What kind of growth are you expecting in contract business and the fall that you are seeing in Carbogen itself stop or do you see a turnaround there?

A: We are expecting normal growth next year of about 7-10% over the current year. The consolidated growth of 20%, which we are talking of, will come largely from contract manufacturing business and that too from India.

Q: You have just completed a plant where I believe you have spent about USD 20 million on it, an API facility. How much of it will be under utilization and how much will it produce a year? Overall, how much of your facilities are under full utilization or 80 or 60%? If you could talk about this plant first and how much revenue it produces?

A: We have completed two new plants. One plant in Bavla in India, which is the plant for manufacturing oncology and high potency drugs, we are not expecting huge revenues from this in FY11. In FY12 only the major revenue will come. In FY11, we are expecting 5 million of turnover from that and in second half only it would go to commercial sales.

We completed another plant in China for API. The valuations are going on right now and that also somewhere in H2FY11, we will start commercial operations. There also we expect 5 million in first year.